Summary of Vacina contra câncer de pele irá entrar na fase final de testes | Jornal da Band

00:00:00 - 00:00:00

In the "Jornal da Band" YouTube video, it was announced that a new vaccine for melanoma, the most severe type of skin cancer, is approaching the final phase of testing this year. Produced by Moderna and Merk, the vaccine uses the same technology as COVID-19 vaccines and has shown a 49% reduction in death risk in patients. Personalized for each patient using artificial intelligence and DNA sequencing, the vaccine identifies cancer cells and triggers the immune system to attack them. The final phase of testing, led by the University of London and involving over 1,000 volunteers, could lead to regulatory approval and public availability as early as next year. Estimated to cost around R$ millions per patient, the vaccine may also be effective against other types of cancer, such as colon, rectum, and pancreas.

• 00:00:00 In this section of the "Jornal da Band" YouTube video, it was announced that a new vaccine for the most severe type of skin cancer, melanoma, is set to enter the final phase of testing this year. The vaccine, produced by Moderna and Merk, uses the same technology that helped combat the COVID-19 pandemic and has reduced the risk of death in patients by 49%. The vaccine, which is personalized for each patient using artificial intelligence and DNA sequencing, identifies cancer cells and alerts the body's immune system to attack them. The final phase of testing, led by the University of London, will involve over 1,000 volunteers, and if all goes as planned, the vaccine could receive regulatory approval and be available to the public as early as next year. The cost of the treatment, estimated to be around R$ millions per patient, may also be effective against other types of cancer, such as colon, rectum, and pancreas.